Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).
Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a pati
Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro